Abstract: A novel combination comprising the 17 ?-hydroxylase/C17,20 lyase inhibitor, (3?)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol or a pharmaceutically acceptable salt or solvate thereof, with a PI3K? inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 ?-hydroxylase/C17,20 lyase and/or PI3K? is beneficial, e.g., cancer.

Abstract: Compositions, formulations, methods, and systems for treating thyroid eye disease and related conditions (e.g., Grave's Ophthalmopathy). The methods described herein include administering, to a patient in need, systemic or local beta adrenergic agonists (e.g., as an extended release crystalline microparticle suspension). The methods can further include administering a compound for reducing beta adrenergic receptor desensitization (e.g., a corticosteroid) prior to administering or coadministered with the beta adrenergic agonist. The methods can also include locally administering to the eye an immunosuppressant agent (e.g., rapamycin) prior to administering a beta adrenergic agonist. The compositions described herein include ophthalmic pharmaceutical formulations of beta adrenergic agonists in the form of extended release crystalline microparticle suspensions or mixtures of the crystalline microparticle suspensions with beta adrenergic agonist solutions.

Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.

Abstract: The present invention relates to salicylates for use in the cancer.

Abstract: The present invention provides a stable, organoleptically acceptable topical formulation(s) of the tetracycline antibiotics or pharmaceutically acceptable salts or hydrates thereof for the treatment of acne.

Abstract: A topical composition for treatment of a skin condition comprising a fluorescent, photosensitive, or oxygen sensitive active ingredient encapsulated in a plurality of tubular microparticles for pharmaceutical use in humans is described. Some embodiments comprise a topical composition for treatment of acne that comprises an encapsulation of a tetracycline class drug, such as crystalline minocycline, in a plurality of microparticles, wherein the microparticles comprise a divalent cation, such as Mg2+ or Zn2+. The tubular microparticles may comprise Mg2CO3. Benefits of various embodiments include the lack of visible fluorescence from a fluorescent active ingredient, reduced UV degradation of a photosensitive active ingredient, reduced UV degradation of an oxygen sensitive active ingredient, sun protection factor for the skin, and sustained delivery of a therapeutic dose.

Abstract: Compositions and foods which contain (1) histidine and (2) vitamin B6 and/or carnosine are useful for treating, improving, and recovering from fatigue.

Abstract: One embodiment relates to a mycotoxin adsorbent highly specific for A and B trichothecenes, and especially for vomitoxin (or deoxinivalenol) and T-2 toxin; as well as a process for the preparation of the mycotoxin adsorbent. The adsorbent may be obtained by modifying the surface of an aluminum silicate using an organic functionalized-chain compound which provides it with high polarity properties. The adsorbent may be used in the preparation of balanced animal feed that avoids the toxic effects of the trichothecenes present in the feed. The combination of the adsorbent with aluminum silicates or organic aluminum silicates may be used for the preparation of balanced animal feeds that avoid the toxic effects of mycotoxins.

Abstract: The present invention relates to a composition comprising at least one fucosylated oligosaccharide, for use in preventing and/or treating URT infections in an infant or young child fulfilling at least one of the following criteria: i) the infant or young child is born from a non-secretor mother and/or is fed with a mother's milk deficient in at least one fucosylated oligosaccharide(s) ii) the infant or young child has at least one sibling iii) the infant or young child was born by C-section.

Abstract: The invention relates to HMOs and compositions comprising thereof for reducing the risk of, preventing, or treating CVD and/or CDV associated pathological conditions or diseases in humans, particularly in overweight and obese humans.

Abstract: A molecule responding to formula (I)of the glycocluster type with galactose residues at their extremities. Simple and efficient methods for the preparation of these compounds. Medical use of compounds (I) as inhibitors of infections by Pseudomonas aeruginosa, more specifically as inhibitors of Pseudomonas aeruginosa's virulence.

Abstract: Aspects of the invention relate to methods for producing NAD precursors such as nicotinamide mononucleotide (NMN), comprising providing an isolated cell that overexpresses a nicotinamide phosphoribosyltransferase (Nampt) enzyme and culturing the cell in the presence of nicotinamide (NAM).

Abstract: The present invention relates to methods of treating or decreasing the likelihood of developing a disorder associated with immune misregulation, such as, an autoimmune disorder, or viral or virus-associated disorder in a subject including administering to the subject a composition comprising an activator of a CCCH zinc finger-containing PARP, such as, PARP13 or PARP12. The present invention also relates to methods of treating a TRAIL-resistant disorder, such as, TRAIL-resistant cancer including administering to the subject a composition comprising an activator of a CCCH zinc finger-containing PARP, such as, PARP13 or PARP12. The present invention further relates to methods of modulating a CCCH zinc finger-containing PARP-RNA interaction including contacting a CCCH zinc finger-containing PARP protein or a CCCH zinc finger-containing PARP fusion protein with a CCCH zinc finger-containing PARP activator.

Abstract: Methods and compositions for treating cancer by intratumorally administering a stimulator of interferon genes (STING) agonist are disclosed herein. In some embodiments, there are provided compositions and methods concerning methods for treating cancer in a subject comprising administering to the subject an effective amount of a stimulator of interferon genes (STING) agonist, wherein the STING agonist is administered intratumorally.

Abstract: The present invention provides formulations for enhancing bioavailability of water-soluble compounds including water-soluble vitamins. The formulations include a water-soluble vitamin and a glycoside selected from a diterpene glycoside and a triterpene glycoside.

Abstract: This document provides methods and materials involved in treating hematological malignancies. For example, methods and materials for using telomerase inhibitors to treat hematological malignancies such as hematological malignancies with a spliceosome mutation genotype or presenting with ringed sideroblasts within bone marrow are provided.

Abstract: The invention relates to methods of treating and preventing radiation damage from whole-body exposure. According to the methods of the invention, subjects are treated therapeutically and/or prophylactically with low-anticoagulant heparinoids. The invention also relates to methods of extending the life of subjects exposed to whole-body radiation.

Abstract: [Problem] To suppress the onset of adverse effects of drugs that cause gastric ulcers as an adverse effect. [Solution] The onset of gastric ulcers induced by a drug is suppressed by incorporating, into a pharmaceutical composition containing a drug having gastric ulcers as an adverse effect, a high-molecular polysaccharide that has a molecular weight of 800,000-3,000,000 and that produces a gel when a 0.3% aqueous solution thereof is added dropwise to artificial gastric juice.

Abstract: A composition and method of providing nitric oxide and nitrite therapy to patients whereby a therapeutic amount is bioavailable within approximately 30 minutes of administration. In embodiments of the invention, nitric oxide is produced in the oral cavity.

Abstract: A composition including a hydrate form of magnesium oxide, denoted as MgO.(H2O)n, at a concentration ranging from 1 to 100 weight percent (wt %), where n is any value from 0.1 to 2. The composition may further include MgO at a concentration ranging from 0 to 99 wt %; or Mg(OH)2, at a concentration ranging from 0 to 99 wt %; or Mg(OH)2 at a concentration ranging from 0 to 99 wt %, and MgO, at a concentration ranging from 0 to 99 wt %.

Abstract: The present disclosure provides a method for killing persister cells with mitomycin C and/or cisplatin, or derivatives thereof. Recalcitrant infections are difficult to treat due to persister cells, a subpopulation of all bacterial populations that is highly tolerant against all traditional antibiotics since the cells are dormant and antibiotics are designed to kill growing cells. Here, we show that MMC and cisplatin eradicate persister cells through a growth-independent mechanism, cross-linking DNA. We find both agents are effective against both planktonic cultures and highly robust biofilm cultures for a broad range of bacterial species, including commensal Escherichia coli K-12 as well as pathogenic species of E. coli, Staphylococcus aureus, and Pseudomonas aeruginosa. In certain approaches cisplatin is superior to MMC.

Abstract: Stabilized multi-component antimicrobial compositions for treating tissue diseases, infections or conditions include a first and second set of differently sized and/or differently shaped metal nanoparticles, and a stabilizing agent. Compositions and treatment methods may be used for treating tissue diseases, infections or conditions caused by microbial infections, such as bacteria, viral, and/or fungal infections, or for preventing the infection of a wound, such as a cut, abrasion, ulcer, lesion, sore, and the like. The compositions and treatment methods disclosed herein may also be used as a prophylactic, and in some embodiments may be applied to otherwise healthy tissue in order to prevent or reduce the occurrence of a tissue disease, infection or condition.

Abstract: Provided are methods and kits for safe and effective therapy that can be administered early after a heart attack in order to prevent progressive heart dilatation and resultant loss of function. The therapy includes the administration of particulate compositions to a region comprising an infarct or a portion thereof.

Abstract: The present invention relates to solid compositions, preferably in powder or granule form, based on minerals (semi-finished or raw material) and a process for preparing said solid compositions. Furthermore, the present invention relates to solid formulations (final products) and orally disintegrating formulations (final products) containing said solid compositions. Moreover, the present invention relates to a process for preparing said solid formulations and said orally disintegrating formulations. Finally, the present invention relates to the use of said solid compositions or said solid or orally disintegrating formulations in the treatment of disorders or diseases related to or derived from a deficiency of minerals such as magnesium (II), calcium (II), iron (III), zinc (II) and/or iodine. All the compositions or formulations of the present invention are suitable for pediatric subjects, adolescents, athletes, men, women, pregnant women and elderly.

Abstract: The present subject matter relates to a method of manufacturing an AFOD intravenous injection, comprising dissolving a Fraction IV1+IV4 paste with WFI; adding sodium acetate, adjusting pH and agitating until fully dissolved; cooling; performing press filtration; collecting an AFOD paste comprising newly-found proteins KH 24, KH 25, KH 26, and KH 27; dissolving the paste with a buffer; centrifuging; filtrating with a depth filter; adding Tween-80; cooling; adjusting pH and adding a cold alcohol while cooling; centrifuging to obtain a second AFOD paste; dissolving the second paste with a buffer and adjusting pH; filtrating with a depth filter; ultra-filtrating; undergoing dialysis with WFI; nano filtrating for virus removal; concentrating and adjusting pH; adding a stabilizer; and filling and performing sterile filtration to obtain the AFOD intravenous injection. The present subject matter relates to an AFOD intravenous injection in liquid or lyophilized form to prevent and kill HIV-1 and HIV-2.

Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.

Abstract: The invention relates to the use as a drug or medical nutritional product in humans to treat a pathological dysbiosis and/or to prevent or treat at least one derived metabolic disease chosen from among excess weight with comorbidity, obesity, diabetes, heart and vascular diseases, atherosclerosis, degenerative bone disease, neurodegenerative disease, metabolism-related cancers, autoimmune diseases, steatosis, metabolic steatohepatitis, and chronic inflammatory diseases of the intestine, by increasing the Christensenella bacterial genus in the intestine, of a composition comprising a mixture of active ingredients consisting of at least: a whey hydrolysate with a molecular weight comprised between 200 and 10,000 Daltons, a whey isolate and/or a concentrate, and calcium caseinate.

Abstract: The invention relates to a method for treating or preventing the development of emotion and/or mood disorders in a human individual.

Abstract: A method for treatment of peripheral arterial disease conditions comprising systemically administering an effective amount of therapeutic stem cells. Included within the scope of the invention is intravenous administration of a therapeutic amount of ischemic tolerant mesenchymal stem cells in the treatment of peripheral arterial disease.

Abstract: Microcapsules are described that comprise (a) a liquid aqueous or hydrogel core; (b) a semipermeable membrane surrounding said core; (c) live animal cells (e.g., pancreatic cells) in the core; and (d) oxygen-generating particles in said core, said oxygen-generating particles included in said microcapsules in an amount sufficient to lengthen the duration of viability of said animal cells in said microcapsules. Compositions comprising such microcapsules and uses thereof, such as in treating diabetes, are also described.

Abstract: The invention relates to preparations and methods of creating preparations of reconstituted amniotic membrane denuded of the amniocyte/epithelial cell layer to preserve amniocytes viability during processing. The tissue graft utilizes amniotic fluid as a source of additional viable stem cells. The amniotic tissue graft is flowable and injectable, and designed for use in surgical and minimally invasive medical therapy of injury and disease to promote tissue regeneration and healing. The tissue grafts optimize available quantities of viable mesenchymal stem cells and non-cellular bioactive compounds to enhance therapeutic efficacy. The tissue grafts are semi-viscous fluids which may be intraoperatively transplanted at the recipient site using a needless syringe or by non-operative percutaneous injection through a hypodermic needle.

Abstract: Methods for treating joint diseases, disorders, and conditions, such as osteoarthritis, with a composition containing a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) are provided. The composition can contain TIMPs as part of amniotic fluid, or the TIMPs can be isolated from another source or recombinantly produced. The methods are particularly useful for treating osteoarthritis associated with degradation of articular cartilage by proteases. Also provided are methods of lubricating a joint, such as an osteoarthritic joint.

Abstract: Disclosed herein are methods for preventing or treating a lung disorder using, in part, mesenchymal stem cells derived from umbilical cord tissue. The methods and uses described herein relate to the administration of or use of mesenchymal stem cells, specifically those isolated and/or enriched from umbilical cord tissue, to a subject in need thereof having a lung disorder.

Abstract: A tissue repair material derived from fish skin and manufacturing method thereof is applied to provide the tissue repair material suitable for use as a patch, a cover, a carrier, a scaffold, an implant or a reagent in various tissues. The tissue repair material has collagens to improve the wounded tissue repair, and has particular characters for desired tissue repair application. Furthermore, so far the factors of the terrestrial animal transmitted disease (caused by virus) do not survive on the tissue repair material derived from fish skin.

Abstract: Several embodiments of the invention provide a unique system of formulations adapted to beneficially alter the microbiome. In one embodiment, the invention comprises four oral formulations designed to work synergistically to assist in weight management. The formulations include three or four of the following: a cleansing formulation, a prebiotic formulation a probiotic formulation and a nutritional formulation. The formulations can be designed to work together to fundamentally change the flora of the gastrointestinal tract to achieve significant benefits.

Abstract: The present invention relates to strain of Lactobacilli and compositions containing the strain for use in modifying the absorption of cholesterol in an individual or the treatment of heart disease, diabetes or obesity.

Abstract: Macroalgae compositions, processes for the preparation thereof, and applications thereof as a sports nutrition supplement are described. More particularly, a macroalgae composition includes a macroalgae extract including medium chain and long chain fatty acids in a ratio of about 1:0.0005 to 1:0.1. The composition is prepared by extracting macroalgae selected from green, red and/or brown algae or the combinationsusing suitable non-polar, semi-polar and polar organic and/or inorganic solvents and the combinations thereof. The composition is useful as a sports nutrition supplement in an effective daily dose, and enhances exercise endurance, resistance to muscle fatigue and/or supports protein synthesis performance. The composition is safe for human consumption and is useful as sports nutrition and for body building applications.

Abstract: Methods are described for improving sexual health by administering a composition in an effective amount to a subject in need thereof. More particularly, methods are described for improving sexual health by administering a macroalgae composition including a macroalgae extract, comprised of saturated and unsaturated fatty acids in a ratio of at or about 1:0.5 to at or about 1:10. The composition is prepared by solvent extraction of macroalgae selected from green, red and/or brown seaweeds or the combinations thereof. Effects are evaluated on biomarkers related to sexual health such as testosterone synthesis, nitric oxide synthesis, phosphodiesterase 5 and 11.

Abstract: The present invention relates to an extract of algae from the order of ulvales, in particular an extract of green algae of the Ulva type, for its use for modulating the immune response in a human being or an animal, in particular for stimulating the immune response with view to infections. It also relates to the non-therapeutic use of an extract of green algae of the Ulva type for modulating the immune response.

Abstract: The present invention relates to a pharmaceutical composition comprising, as active substance, Saccharomyces boulardii yeast cells, for use for reducing body fat in an individual.

Abstract: The present invention relates to a feed supplement which comprises a resin acid based composition comprising over 10% (w/w) resin acids for use in the prevention of growth of harmful bacteria in the animal digestive tract, in the prevention of intestinal disorders, in the modulation of microbial population of the animal digestive tract, in enhancing rumen fermentation, lowering rumen methane production and/or in binding toxins. The invention further relates to a use of the feed supplement and a feed composition comprising the feed supplement.

Abstract: The present invention relates to a solid preparation including a Pelargonium sidoides extract and a silicic acid compound, which is allowed to be formulated in a solid form by direct adsorption of the Pelargonium sidoides extract onto a silicic acid compound, and a preparation method thereof. Since the solid preparation including the Pelargonium sidoides extract and the silicic acid compound of the present invention has higher stability than a liquid preparation such as syrup, and has no additives such as sugars, there is no concern about microbial contamination or spoilage of the preparation. In addition, it is possible to pack the solid preparation individually. Since the solid preparation is smaller in volume than the liquid preparation, it is highly portable, and there is also a convenience that no additional tools are needed to take the drug. Further, the active ingredient can be taken at the equal amount every time.

Abstract: The present invention provides methods of extracting Cannabis plant material through use of aloe, compositions comprising the resulting Cannabis aloe extracts, methods of using the extracts to ameliorate skin conditions, and applicators for applying the extracts topically.

Abstract: A process for extracting antioxidants from a plant, including contacting a plant material from a guayusa plant for a first time with a solvent, thereby obtaining a first slurry, filtering said first slurry, thereby obtaining a first extract, contacting said plant material for a second time with said solvent, thereby obtaining a second slurry, filtering said second slurry, thereby obtaining a second extract, combining said first extract and said second extract, thereby generating an third extract containing at least antioxidants, xanthines, and amino acids, and substantially drying said third extract.

Abstract: The invention relates to therapeutic uses of gum mastic, and compounds found therein including polymeric myrcene. More particularly, the invention relates to methods of treating impaired neurological function using compositions comprising polymeric myrcene.

Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.

Abstract: Described are herbaceutical effervescent formulations comprising extracts of Eurycoma longifolia and uses thereof.

Abstract: Use of dietary fibre material extracted from sugar cane in the manufacture of a food product that is formulated to ameliorate the effects of acid reflux and extended symptoms of gastro-oesophageal reflux disease. The product ameliorates both the acute and long term symptoms of both conditions.

Abstract: In an aspect, the present disclosure provides a composition for moisturizing skin, which contains a bamboo sap and a betaine as active ingredients. Specifically, the composition exhibits skin moisturizing effect by regulating natural moisturizing factors (NMFs) and is useful as a cosmetic composition, a pharmaceutical composition or a health food composition effective in moisturizing skin.

Abstract: A biogel, and kits, agents, and methods for formation of the biogel are described. The biogel can be used for a variety of applications, including haemostasis, wound sealing, tissue engineering or localised drug delivery.